Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Interim Report for the 6 months ended June 30, 200721 Aug 2007
Genmab Announces 2007 First Half Year Results21 Aug 2007
Roche Files IND for Second Genmab Antibody10 Aug 2007
Genmab Regains Rights to HuMax-TAC2 Aug 2007
Genmab A/S Articles of Association dated June 27, 20079 Jul 2007
Genmab's Total Number of Voting Rights and Total Share Capital29 Jun 2007
Genmab Regains Rights to HuMax-CD429 Jun 2007
Genmab Announces Final HuMax-CD4 Phase II CTCL Data
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
29 Jun 2007
Grant of Warrants to Board Members, Management and Employees in Genmab A/S27 Jun 2007
Genmab Reaches First Milestone in Ofatumumab Collaboration26 Jun 2007
Genmab Announces Development Plans for Ofatumumab18 Jun 2007
GlaxoSmithKline and Genmab Present Positive Phase II Results with Ofatumumab in Patients with Rheumatoid Arthritis (RA)15 Jun 2007
  • Previous
  • 1
  • More pages
  • 118
  • 119
  • 120
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863